Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
Tóm tắt
Oncogenic overexpression of integrin-β7 (ITGB7) in cases of high-risk multiple myeloma (MM) was reported to promote enhanced interactions between neoplastic plasma-B cells and stromal cells to develop cell-adhesion mediated drug resistance. Expression profiles of adhesion related genes were analyzed in a cohort of MM patients containing major IgH translocations or hyperdiploidies (HY), diagnosed at the premalignant monoclonal gammopathy of undetermined significance (MGUS; n = 103), smoldering multiple myeloma; (SMM; n = 190) or MM (MM; n = 53) stage. Differential expression was integrated with loci-specific alterations in DNA-methylation and chromatin marks in MM patients. A CRISPR-based targeted induction of DNA-methylation at the ITGB7 super-enhancer (SE) in MM.1S cells was employed to intersect the impact of cis-regulatory elements on ITGB7 expression. ITGB7 was significantly (p < 0.05) upregulated in patients with t(14;16) and t(14;20) subgroups in all MGUS, SMM and MM stages, but sporadically upregulated in t(4;14) subgroup at the MM stage. We demonstrate a predetermined enhancer state on ITGB7 in primary-B cells that is maintained under bivalent chromatin, which undergoes a process of chromatin-state alterations and develops into an active enhancer in cases of the t(4;14) subgroup or SE in cases of the t(14;16) subgroup. We also demonstrate that while targeted induction of DNA-methylation at the ITGB7-SE further upregulated the gene, inhibition of ITGB7-SE-associated transcription factor bromodomain-4 downregulated expression of the gene. Our findings suggest an epigenetic regulation of oncogenic overexpression of ITGB7 in MM cells, which could be critical in MM progression and an attractive therapeutic target.
Tài liệu tham khảo
Kazandjian, D. in Seminars in oncology. 676–681 (Elsevier).
Zhan F, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8. https://doi.org/10.1182/blood-2005-11-013458.
Meißner T, et al. Gene expression profiling in multiple myeloma—reporting of entities, risk, and targets in clinical routine. Clin Cancer Res. 2011;17:7240–7. https://doi.org/10.1158/1078-0432.ccr-11-1628.
Kaiser MF, et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia. 2013;27:1754–7. https://doi.org/10.1038/leu.2013.12.
Lohr JG, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer cell. 2014;25:91–101. https://doi.org/10.1016/j.ccr.2013.12.015.
Choudhury SR, et al. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020;13:1–15.
Walker BA, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587–97.
Kumar SK, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011;118:4359–62. https://doi.org/10.1182/blood-2011-03-342089.
Sonneveld P, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–62. https://doi.org/10.1182/blood-2016-01-631200.
Chng WJ, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982–9. https://doi.org/10.1158/0008-5472.Can-06-4046.
Sharma A, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. WIREs Syst Biol Med. 2010;2:654–69.
Choudhury, S. R. & Walker, B. A. in The DNA, RNA, and Histone Methylomes 543–572 (Springer, 2019).
Kaiser MF, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013;122:219–26.
Neri P, Bahlis NJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targ. 2012;12:776–96. https://doi.org/10.2174/156800912802429337.
Hatano K, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231–42.
Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int J Hematol. 2016;104:281–92.
Ren Z, et al. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. J Hematol Oncol. 2021;14:11. https://doi.org/10.1186/s13045-021-01031-3.
Neri P, et al. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood. 2011;117:6202–13. https://doi.org/10.1182/blood-2010-06-292243.
Katz BZ. Adhesion molecules–The lifelines of multiple myeloma cells. Semin Cancer Biol. 2010;20:186–95. https://doi.org/10.1016/j.semcancer.2010.04.003.
Usmani SZ, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761.
Shaughnessy JD Jr, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–84.
Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335.
Munshi NC, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117:4696–700.
Qiang Y-W, et al. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016;128:2919–30. https://doi.org/10.1182/blood-2016-03-706077.
Hurt EM, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5:191–9. https://doi.org/10.1016/s1535-6108(04)00019-4.
Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927–37.
Annunziata CM, et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood. 2011;117:2396–404. https://doi.org/10.1182/blood-2010-04-278788.
Gavile CM, et al. CD86 regulates myeloma cell survival. Blood Adv. 2017;1:2307–19. https://doi.org/10.1182/bloodadvances.2017011601.
Kikuchi J, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood J Am Soc Hematol. 2010;116:406–17.
Kikuchi J, et al. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Investig. 2015;125:4375–90.
Bergsagel PL, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303. https://doi.org/10.1182/blood-2005-01-0034.
Irizarry RA, Gautier L, Cope LM. The analysis of gene expression data. Berlin: Springer; 2003. p. 102–19.
Choudhury SR, Walker BA. Multiple Myeloma 179–191. Berlin: Springer; 2018.
Aschenbrenner D, et al. An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells. Nat Immunol. 2018;19:1126–36. https://doi.org/10.1038/s41590-018-0200-5.
Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007;8:215. https://doi.org/10.1186/gb-2007-8-5-215.
Di Marzo L, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016;7:60698.
Roy Choudhury S, Ashby C, Zhan F, van Rhee F. Epigenetic deregulation of telomere-related genes in newly diagnosed multiple myeloma patients. Cancers. 2021;13:6348.
Li Y, Chen X, Lu C. The interplay between DNA and histone methylation: molecular mechanisms and disease implications. EMBO Rep. 2021;22:e51803. https://doi.org/10.15252/embr.202051803.
Zhang H, et al. A mutation that blocks integrin α4β7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis. BMC Biol. 2020;18:64. https://doi.org/10.1186/s12915-020-00784-6.
Delmore JE, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17. https://doi.org/10.1016/j.cell.2011.08.017.
Xu L, et al. Cell adhesion molecule CD166 drives malignant progression and osteolytic disease in multiple myeloma. Cancer Res. 2016;76:6901–10. https://doi.org/10.1158/0008-5472.Can-16-0517.
Chang H, Qi Q, Xu W, Patterson B. c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia. 2007;21:1572–4. https://doi.org/10.1038/sj.leu.2404669.
Martinez-Garcia E, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117:211–20. https://doi.org/10.1182/blood-2010-07-298349.
Popovic R, et al. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet. 2014;10:e1004566. https://doi.org/10.1371/journal.pgen.1004566.
Beacon TH, et al. The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes. Clin Epigenet. 2021;13:138. https://doi.org/10.1186/s13148-021-01126-1.
Zentner GE, Tesar PJ, Scacheri PC. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res. 2011;21:1273–83. https://doi.org/10.1101/gr.122382.111.
Van Stralen E, et al. Identification of primary MAFB target genes in multiple myeloma. Exp Hematol. 2009;37:78–86.